What are the recommended management strategies for patients based on their lipid‑core burden index (LCBI) score?

LCBI Score Management Strategies

The lipid-core burden index (LCBI) is a research tool measured by near-infrared spectroscopy (NIRS) that identifies lipid-rich plaques during coronary intervention, but current major lipid management guidelines do not incorporate LCBI scores into treatment algorithms—management should instead follow standard risk-based LDL-C targets regardless of LCBI values.

Understanding LCBI in Clinical Context

The LCBI and its derivative maxLCBI4mm (maximum LCBI over any 4-mm segment) quantify lipid content within coronary plaques during catheterization. While research demonstrates that:

• High LCBI values (maxLCBI4mm ≥354-400) predict procedural complications including slow TIMI flow and coronary microvascular dysfunction during PCI 1, 2
• LCBI correlates with plaque vulnerability and progression of cardiac allograft vasculopathy 3
• Measurements show excellent reproducibility (ICC 0.91-0.95) with contemporary NIRS-IVUS catheters 4

However, LCBI is not mentioned in any major lipid management guidelines including the 2024 ESC, 2021 Canadian, 2020 AHA/ACC, or 2019 ESC/EAS dyslipidemia guidelines 5, 6, 7, 8.

Evidence-Based Management Algorithm

For Secondary Prevention Patients (Established ASCVD)

Regardless of LCBI findings, follow this treatment pathway:

1. Initiate high-intensity statin therapy immediately targeting LDL-C <55 mg/dL (1.4 mmol/L) with ≥50% reduction from baseline 8, 7

2. If LDL-C remains ≥70 mg/dL (1.8 mmol/L) on maximally tolerated statin:

   • Add ezetimibe as second-line therapy 8
   • If still ≥70 mg/dL after statin + ezetimibe, add PCSK9 inhibitor 7, 8

3. For very high-risk patients (recent ACS, recurrent events within 2 years, polyvascular disease, diabetes with target organ damage):

   • Consider LDL-C goal <40 mg/dL (1.0 mmol/L) 8
   • PCSK9 inhibitors may be added directly with or without ezetimibe in this subset 7

Impact of LCBI on Lipid-Lowering Intensity

Research suggests aggressive LDL-C lowering may reduce LCBI values:

• Achieving LDL-C <55 mg/dL showed greater maxLCBI4mm reduction compared to LDL-C 55-70 mg/dL in non-culprit lesions 9
• Plaques with maxLCBI4mm ≥400 converted to <400 more frequently with very low LDL-C (36% vs 4%, p=0.001) 9
• However, a meta-analysis found no statistically significant overall LCBI reduction with lipid-lowering therapy (SMD -0.18, p=0.15), though the direction favored intensive treatment 10

Critical Caveats

Do not use LCBI to determine lipid therapy intensity. The evidence shows:

• LCBI measurements occur during invasive procedures, not as screening tools
• No guideline-endorsed LCBI thresholds exist for initiating or intensifying lipid therapy
• Standard risk stratification (clinical ASCVD, diabetes, calculated risk scores) drives treatment decisions 5

Procedural considerations: If NIRS-IVUS reveals maxLCBI4mm ≥354-579 during PCI, operators should anticipate higher risk of slow flow and consider adjunctive measures (distal protection, careful lesion preparation) 1, 2, but this does not alter post-procedure lipid management targets.

Practical Application

For patients undergoing PCI with high LCBI findings:

• Ensure maximally intensive statin therapy (atorvastatin 80mg or rosuvastatin 40mg) 8
• Measure LDL-C 4-12 weeks post-procedure
• Add ezetimibe if LDL-C ≥70 mg/dL
• Pursue PCSK9 inhibitor if LDL-C remains ≥70 mg/dL on statin + ezetimibe 7

The treatment algorithm remains identical whether LCBI is high or low—the goal is achieving guideline-recommended LDL-C targets based on cardiovascular risk category, not LCBI values 5, 8.